Skip to main content

Advertisement

Table 3 Cox proportional hazards model with CTC BL

From: Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

  PFS OS
  Hazard ratio 95% CI P Hazard ratio 95% CI P
Baseline CTC status (CTC BL )
 < 5 CTC (CTCBL-) 1.00    1.00   
 ≥ 5 CTC (CTCBL+) 1.55 1.19–2.01 0.001 2.79 2.04–5.63 < 0.001
Age at inclusion
 Per year 0.99 0.98–1.00 0.207 1.00 0.99–1.01 0.938
Number of metastatic sites
 One site 1.00    1.00   
 Multiple sites 0.97 0.66–1.43 0.892 0.71 0.41–1.23 0.227
Site of metastasis
 Bone 1.00    1.00   
 Visceral/local 0.98 0.67–1.46 0.939 1.75 1.00–3.01 0.052
 Both 1.07 0.71–1.63 0.739 2.55 1.41–4.60 0.002
Line of therapy
 1 1.00    1.00   
 2 1.35 0.93–1.95 0.113 1.45 0.92–2.28 0.112
 ≥ 3 1.91 1.40–2.59 < 0.001 2.01 1.37–2.96 < 0.001
Molecular Subtypes
 HR+/HER2- 1.00 °   1.00   
 HER2+ 1.10 0.79–1.52 0.577 1.09 0.72–1.63 0.695
 TNBC 1.92 1.36–2.71 < 0.001 2.86 1.91–4.27 < 0.001
  1. Bold P values indicate statistical significance.
  2. HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.